FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEM	IENT	OF	CHA	NGE

05/04/2004

05/04/2004

OMB APPROVAL OMB Number: 3235

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BUCKNUM THOMAS J			2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
			BIOGEN IDEC INC [BIIB]	`	Director Officer (give title	10% Owner Other (specify				
(Last) (First) (Middle) L	3. Date of Earliest Transaction (Month/Day/Year)	X	below) `	below)						
14 CAMBRIDGE CENTER			05/04/2004		EVP and General Counsel					
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	nendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check App Line)						
CAMBIRDGE MA 02142		X	Form filed by One Reporting Person							
(City)	(State)	(Zip)			Form filed by More that Person	an One Reporting				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 2. Transaction 2A. Deemed 3. Transaction Code (Instr. 5. Amount of 7. Nature 6. Ownership Form: Direct (D) or Indirect of Indirect Beneficial Execution Date, (Month/Day/Year) 5) Beneficially if any (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) Code ν Price Amount (Instr. 3 and 4) Common Stock 05/04/2004 M 5,000 \$13.4 80,500 D Α Common Stock 05/04/2004 S 5,000 D \$58.66 75,500 D Common Stock 05/04/2004 10,000 A 75,500 D M \$13.4 65,500 Common Stock 05/04/2004 S 10,000 D \$58.62 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

M

S

20,000

20,000

Α

D

\$13.4

\$58.6

65,500

45,500

9,000

D

D

D

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Servitive Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right-to- buy) ⁽¹⁾⁽²⁾	\$13.4	05/04/2004		М			5,000	(2)	04/22/2006	Common Stock	5,000	(1)	75,500	D	
Employee Stock Option (right-to- buy) ⁽¹⁾	\$13.4	05/04/2004		М			10,000	(2)	04/22/2006	Common Stock	10,000	(1)	65,500	D	
Employee Stock Option (right-to- buy) ⁽¹⁾	\$13.4	05/04/2004		М			20,000	(2)	04/22/2006	Common Stock	20,000	(1)	45,500	D	

Explanation of Responses:

Common Stock

Common Stock

Common Stock

- 1. Granted under Issuer's Employee Stock Option Plan, in an exempt transaction under SEC rule 16b-3(d).
- 2. The stock option became exerciseable in six (6) equal installments, commencing one year after the grant date of 04/22/96

Remarks:

By: Benjamin S. Harshbarger For: Thomas J. Bucknum

05/05/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

I, the undersigned, a director and/or an executive officer of Biogen Idec Inc., hereby authorize and designate Thomas J. Bucknum, Anne Marie Cook, Jo Ann Taormina, and Benjamin S. Harshbarger and each of them acting alone, as my attorney-in-fact to execute and file on my behalf any and all Forms 3, 4 and 5 (including any amendments thereto) that I may be required to file with the United States Securities and Exchange Commission as a result of ${\tt my}$ ownership of or transactions in securities of Biogen Idec Inc. The authority granted under this power of attorney shall continue for so long as I am required to file Forms 3, 4 and 5 with regard to my ownership of or transactions in securities of Biogen Idec Inc., unless earlier revoked in writing, but shall terminate automatically as to each individual attorney-in-fact when such person is no longer an employee of Biogen Idec Inc. I acknowledge that the attorneys-in-fact appointed hereunder are not assuming, nor is Biogen Idec Inc. assuming, any of my responsibility to comply with Section 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this instrument to be duly executed this $2nd\ day\ of\ February,\ 2004.$

/s/ Thomas J. Bucknum

Thomas

J. Bucknum